Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) completed its acquisition of Emalex Biosciences for $700 million, with potential additional ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE